BSP Pharma oils its wheels with a DKK 15 million investment  

Aarhus Oliefabrik pumps DKK 15 million into BSP Pharma to develop new drugs for psoriasis and herpes

Aarhus Oliefabrik (Aarhus Oil Factory) is pumping DKK 15 million (USD 2.1 million) into pharmaceutical company BSP Pharma to further develop its new drugs for psoriasis and herpes. BSP Pharma is jointly owned by Aarhus Oliefabrik and the pharmaceutical company Astion; following the new deal Aarhus Oliefabrik will acquire a 70.7% share ownership of BSP Pharma. The new investment will solely be used for clinical trials of the new products planned for Q4 2003/Q1 2004, the time of year when there are most outbreaks of psoriasis and herpes. BSP Pharma has two other pipeline drugs under development, for arthritis and eczema respectively.


All four products in BSP Pharma’s development portfolio are based on a patented technology developed by Astion. The active ingredients which have an anti-inflammatory effect are being produced from the oil of the African shea nut, of which Aarhus Oliefabrik is coincidentally the world’s leading manufacturer. The MD of Aarhus Oliefabrik comments that tests in cell culture and animal models have had very positive results, so the company believes it is on the right development track. The news is reported by

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×